{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:23:11Z","timestamp":1786123391348,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.fjurol.2026.103132","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:24:10Z","timestamp":1779290650000},"page":"103132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Achieving no evidence of disease in metastatic renal cell carcinoma: Consolidative nephrectomy vs ablative therapy"],"prefix":"10.1016","volume":"36","author":[{"given":"Augustin","family":"Zelmar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1586-3995","authenticated-orcid":false,"given":"Victor","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto-Luigi","family":"Cazzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2472-3575","authenticated-orcid":false,"given":"Thibault","family":"Tricard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Moinard-Butot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Gangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2026.103132_bib0115","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.fjurol.2026.103132_bib0120","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2026.103132_bib0125","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2026.103132_bib0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/KCA-190080","article-title":"Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma","volume":"4","author":"Tannir","year":"2020","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.fjurol.2026.103132_bib0135","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2021.05.020","article-title":"Primary renal tumour response in patients treated with nivolumab for metastatic renal cell carcinoma: results from the GETUG-AFU 26 NIVOREN Trial","volume":"80","author":"Courcier","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103132_bib0140","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.eururo.2021.10.001","article-title":"First-line Nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 Trial","volume":"81","author":"Albiges","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103132_bib0145","doi-asserted-by":"crossref","first-page":"v359","DOI":"10.1093\/annonc\/mdz249.007","volume":"30","author":"Albiges","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.fjurol.2026.103132_bib0150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.euros.2022.04.004","article-title":"Molecular heterogeneity between paired primary and metastatic lesions from clear cell renal cell carcinoma","volume":"40","author":"Roussel","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.fjurol.2026.103132_bib0155","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2014.12.036","article-title":"Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma","volume":"67","author":"Gr\u00fcnwald","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103132_bib0160","doi-asserted-by":"crossref","first-page":"e000891","DOI":"10.1136\/jitc-2020-000891","article-title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","volume":"8","author":"Motzer","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.fjurol.2026.103132_bib0165","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.euo.2023.01.010","article-title":"Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR Study","volume":"6","author":"Gr\u00fcnwald","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103132_bib0170","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JU.0000000000001911","article-title":"Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA Guideline: part I","volume":"206","author":"Campbell","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2026.103132_bib0175","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.eururo.2019.12.018","article-title":"Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: a new surgical challenge?","volume":"77","author":"Pignot","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2026.103132_bib0180","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.euo.2022.07.002","article-title":"Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma","volume":"5","author":"Pignot","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103132_bib0185","first-page":"332.e19","article-title":"Delayed partial nephrectomy following complete response to immunotherapy: feasibility and results (UroCCR no157)","volume":"43","author":"Margue","year":"2025","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.fjurol.2026.103132_bib0190","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00270-014-0846-9","article-title":"Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours","volume":"37","author":"Katsanos","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.fjurol.2026.103132_bib0195","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2018180249","article-title":"Image-guided cryoablation for sporadic renal cell carcinoma: three- and 5-year outcomes in 220 patients with biopsy-proven renal cell carcinoma","volume":"289","author":"Breen","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.fjurol.2026.103132_bib0200","series-title":"Edn. presented at the EAU Congress, Madrid","year":"2025"},{"issue":"9","key":"10.1016\/j.fjurol.2026.103132_bib0205","first-page":"4278","article-title":"Development of a risk-stratified approach for follow-up imaging after percutaneous thermal ablation of sporadic stage one renal cell carcinoma","volume":"46","author":"Dreyfuss","year":"2021","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.fjurol.2026.103132_bib0210","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00345-024-05361-y","article-title":"The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma","volume":"43","author":"Pignot","year":"2025","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2026.103132_bib0215","doi-asserted-by":"crossref","first-page":"e2422674","DOI":"10.1001\/jamanetworkopen.2024.22674","article-title":"Health care resource use for modern first-line treatments in metastatic renal cell carcinoma","volume":"7","author":"Shah","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.fjurol.2026.103132_bib0220","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","article-title":"[89Zr]Zr-girentuximab for PET\u2013CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","volume":"25","author":"Shuch","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295039302600063X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295039302600063X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:36:11Z","timestamp":1786113371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295039302600063X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":22,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S295039302600063X"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103132","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achieving no evidence of disease in metastatic renal cell carcinoma: Consolidative nephrectomy vs ablative therapy","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103132"}}